

Regd. Office: Natco House, Road No. 2, Banjara Hills, Hyderabad, Telangana - 500 034.

Phone: +91-40-2354 7532, Website : www.natcopharma.co.in, CIN: L24230TG1981PLC003201

STATEMENT OF AUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31-03-2025

		r	Quarter ended	((//	millions except Year e	
		24.02.0005				
S.No.	Particulars	31-03-2025 Audited	31-12-2024 Unaudited	31-03-2024	31-03-2025	31-03-2024
		(Refer note 4)	Unaudited	Audited (Refer note 4)	Audited	Audited
1	Income Revenue from operations	12,210	4,748	10,683	44,295	39,988
2	Other income	663	1,763	420	3,545	1,281
3	Total income (1+2)	12,873	6,511	11,103	47,840	41,269
4	Expenses					
	Cost of materials consumed	1,690	727	1,276	5,362	5,225
	Purchases of stock-in-trade	408	391	311	1,661	1,514
	Changes in inventories of finished goods, work-in-progress and stock-in-trade	394	(290)	(161)	(125)	427
	Employee benefits expense	1,594	1,416	1,425	5,945	5,250
	Finance costs	102	44	62	239	192
	Depreciation, amortisation and impairment expenses (refer note 7)	983	470	555	2,352	1,868
	Other expenses	2,643	2,116	2,859	9,492	10,058
	Total expenses	7,814	4,874	6,327	24,926	24,534
5	Profit before tax for the period/ year (3-4)	5,059	1,637	4,776	22,914	16,735
6	Tax expense					
	(i) Current tax	1,064	335	903	4,376	3,165
	(ii) Deferred tax Total tax expense	(65) 999	(22)	10 913	(296) 4,080	(313 2,852
_						
7	Profit for the period/ year (5-6)	4,060	1,324	3,863	18,834	13,883
8	Other comprehensive income/ (loss) (net of tax)					
	(i). Items that will not be reclassified to profit or loss:					
	Remeasurement of defined benefit liability/(asset)	(78)	-	(20)	(78)	(20
	Tax on remeasurement of defined benefit liability/(asset)	27	-	7	27	7
	Fair value changes of Equity investments through OCI	(233)	180	(7)	23	97
	Tax impact in Fair value changes on Equity investments through OCI	31 (253)	(26)	2 (18)	(6) (34)	(8
	(ii). Items that will be reclassified to profit or loss:	(200)	104	(10)	(04)	
	Exchange differences on translating financial statements of foreign operations	71	(260)	(107)	(206)	73
		71	(260)	(107)	(206)	73
	Other comprehensive income/ (loss) for the period/ year, net of	(182)	(106)	(125)	(240)	149
	tax	()	(100)	(120)	(=)	
9	Total comprehensive income for the period/ year (7+8)	3,878	1,218	3,738	18,594	14,032
10	Profit for the period/year attributable to:					
10	Owners of the Company	4,066	1,330	3,863	18,854	13,883
	Non-controlling interests	(6)	(6)	-	(20)	-
11	Other comprehensive income for the period/ year attributable to:					
	Owners of the Company	(182)	(106)	(125)	(240)	149
	Non-controlling interests	(102)	-	-	-	-
12	Total comprehensive income for the period/ year attributable to:					
12	Owners of the Company	3,884	1,224	3,738	18,614	14,032
	Non-controlling interests	(6)	(6)	-	(20)	-
13	Paid-up equity share capital (Face value of ₹2 each)	358	358	358	358	358
14	Other equity				75,712	58,173
15	Earnings per share (not annualised for the quarters)					
15	(Face value of ₹2 each)					
	Basic (in ₹)	22.70	7.43	21.56	105.26	77.34
	Diluted (in ₹)	22.70	7.43	21.56	105.26	77.34

Continued..

5

an

NA NA NATCO

derab

See accompanying notes to the audited consolidated financial results.



Consolidated Balance Sheet:		(₹ in millions
	As at 31-03-2025 (Audited)	As at 31-03-2024 (Audited)
I Assets		
(1) Non-current assets	04.040	22.07
(a) Property, plant and equipment (b) Capital work-in-progress	24,319	22,977
(c) Goodwill	2,254 574	1,373
(d) Other intangible assets	2,087	560 1,37
(e) Financial assets	2,007	1,37
(i) Investments	1,528	959
(ii) Other financial assets	1,823	439
(f) Deferred tax assets, net	501	194
(g) Non-current tax assets, net	32	26
(h) Other non-current assets	490	694
Total non-current assets	33,608	28,82
(2) Current assets		
(a) Inventories	7,658	7,00
(b) Financial assets		
(i) Investments	3,208	4,43
(ii) Trade receivables	12,466	11,889
(iii) Cash and cash equivalents	1,200	704
(iv) Bank balances other than (iii) above	20,560	8,82
(v) Loans	94	9
(vi) Other financial assets	4,205	4,52
(c) Other current assets	3,309	2,75
Total current assets	52,700	40,23
Total assets	86,308	69,06
EQUITY AND LIABILITIES (1) Equity (a) Equity share capital (b) Other equity Equity attributable to owners of the Company (c) Non-controlling interest Total equity	358 75,712 76,070 53	358 58,17 58,53
Total equity	76,123	58,53
 (2) Liabilities (A) Non-current liabilities (a) Financial liabilities (ia) Lease liabilities (ii) Other financial liabilities (b) Provisions (c) Deferred tax liabilities (net) Total non-current liabilities 	46 46 656 2 750	53 4(709 2 80 4
(B) Current liabilities		
(a) Financial liabilities		
(i) Borrowings	2,731	3,63
(ia) Lease liabilities	17	2
(ii) Trade payables		
 Total outstanding dues of micro enterprises and small enterprises; and 	176	4
-Total outstanding dues of creditors other than micro enterprises and	2,573	2,31
small enterprises		
(iii) Other financial liabilities	1,146	1,02
(b) Other current liabilities	1,223	1,34
(c) Provisions (d) Current tax linkilities (not)	779	1,02
(d) Current tax liabilities (net)	790	32
Total current liabilities	9,435	9,72
Total liabilities	10,185	10,53
Total equity and liabilities	86,308	69,06
	00,000	Continued





Conco	lidatad	Statement	of	Cach	ELONIC
Conso	iluateu	Statement	. 01	Casil	FIUWS

(₹ in millions)

	Year e	<i>(₹ in millior</i> nded
	31-03-2025 (Audited)	31-03-2024 (Audited)
ash flows from operating activities		
rofit before tax for the period	22,914	16,7
djustments for		
epreciation, amortisation and impairment expenses	2,352	1.8
inance costs		22.412
	239	1
nterest income	(1,872)	(1,0
rovision for impairment of receivables and advances, net	(22)	2
ad debts written off	11	
capital work-in-progresss written off	30	
iabilities written back	(5)	
let (gain)/ Loss on sale of property, plant and equipment and intangible assets	(901)	
Profit)/ loss on sale of investments	(14)	
lividend income on equity investment at fair value through other comprehensive income	(33)	
change in fair value of financial assets measured at fair value through profit and loss	-	
Inrealised foreign exchange gain, net	(8)	
perating profit before working capital changes	22,691	18,0
hanges in working capital:		
ncrease)/ decrease in inventories	(653)	4
ncrease in trade receivables	(593)	(3,4
ncrease)/ decrease in other financial assets	(20)	
ncrease in other assets	(526)	(6
ncrease/ (decrease) in trade payables	(526)	(2)
Decrease) / increase in provisions	5.85353855	(2)
	(381)	
Decrease)/ increase in other financial liabilities	(109)	1
Decrease in other liabilities	(118)	(6
cash generated from operating activities	20,694	14,9
ncome-taxes paid, net of refund	(3,726)	(2,8
let cash generated from operating activities (A)	16,968	12,1
ash flows from investing activities		
Purchase of property, plant and equipment	(4,011)	(3,3
Proceeds from sale of property, plant and equipment	950	(0,0
cquisition of intangible assets	(1,105)	(1)
		(1
roceeds from sale of intangible assets	201	
dvance for purchase of unquoted shares	(30)	
Repayment of loans by others	(4)	
Proceeds from sale of investments	4,102	1,2
Purchase of investments	(3,367)	(2,63
Deposits with banks	(20,576)	(9,2)
Redemption of bank deposits	8,825	
	Contraction of the Contraction o	4,5
nterest received	1,466	5
Dividend received	33	
Redemption of deposits other than with banks	3,848	2,7
Deposits other than with banks	(4,477)	(4,0
let cash used in investing activities (B)	(14,145)	(10,3)
Cash flows from financing activities		
roceeds from issue of shares by subsidiary	73	
ayment on buy-back of shares, including transaction costs and taxes on buy-back		(2,5
let (repayment of)/ proceeds from short-term borrowings (refer note below)	(892)	1,9
Dividends paid	(1,078)	(1,7
inance cost paid	(176)	
		(1
rincipal and interest payment of lease liabilities	(34)	()
let cash used in financing activities (C)	(2,107)	(2,4
let increase/ (decrease) in cash and cash equivalents (A+B+C)	716	(6
	C - (2), 27 (2)	
Cash and cash equivalents as at the beginning of the year	704	1,3
ffect of currency translation adjustment	(220)	
ash and cash equivalents as at the end of the year	1,200	7
ote: Movement in borrowings and lease liabilities in accordance with Ind AS 7:		
urrent borrowings		
Opening balance	3,632	1,
Proceeds from/ (repayment of) borrowings, net	(892)	1,
lon-cash items (foreign exchange changes)	(9)	
	2,731	3,6
ease liabilities	1 1	
Dpening balance	80	
Cash flow changes	(34)	
lon-cash changes	17	1
on outri ondrigoo	63	
	63	
		Continue

3

5

NATCO

derab



Segment reporting:

(₹ in millions except share data)

			Quarter ended		Year ended	Year ended
S.No.	Particulars	31-03-2025	31-12-2024	31-03-2024	31-03-2025	31-03-2024
5.NO.		Audited	Unaudited	Audited	Audited	Audited
		(Refer note 4)		(Refer note 4)		
1	Segment revenue					
•	a. Pharmaceuticals	12,060	4,597	10,746	43,689	38,905
		12,000	4,357		43,089	6101111 C. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1.
	b. Agro chemicals			(63)		1,083
	Add: Unallocated	12,210	4,748	10,683	44,295	39,988
		10.010	4 7 4 0	-	-	-
	Total revenue from operations	12,210	4,748	10,683	44,295	39,988
2	Segment results					
	a. Pharmaceuticals	5,970	1,894	5,368	24,611	17,523
	b. Agro chemicals*	(809)	(213)	(530)	(1,458)	(596)
	Total segment result	5,161	1,681	4,838	23,153	16,927
	Less:	,	.,	.,		,
	a. Finance costs	(102)	(44)	(62)	(239)	(192)
	b. Net unallocated (income)/expenditure	(102)	(++)	(02)	(200)	(102)
	Total profit before tax	5,059	1,637	4,776	22,914	16,735
		0,000	1,007	4,770	22,014	10,100
3	Segment assets					
	a. Pharmaceuticals	53,994	44,021	45,650	53,994	45,650
	b. Agro chemicals	2,712	3,571	4,238	2,712	4,238
	Total segment assets	56,706	47,592	49,888	56,706	49,888
	Add:					
	a. Unallocated	29,602	33,561	19,175	29,602	19,175
	Total assets	86,308	81,153	69,063	86,308	69,063
4	Segment liabilities a. Pharmaceuticals		5 000	5 0 0 7	0.000	5 007
		6,320	5,682	5,807	6,320	5,807
	b. Agro chemicals	314	328	588	314	588
	Total segment liabilities	6,634	6,010	6,395	6,634	6,395
	Add:					2 (1993)
	a. Unallocated	3,551	2,629	4,137	3,551	4,137
	Total liabilities	10,185	8,639	10,532	10,185	10,532 Continued

*During the quarter and year ended 31-03-2025, an impairment loss of INR 500 million is recognised on the property, plant and equipment of Agro Chemical Segment.





Notes to the audited consolidated financial results:

- The audited consolidated financial results of NATCO Pharma Limited ("the Company") and its subsidiaries (together referred as "the Group") have been prepared in accordance with the Indian Accounting Standards (Ind AS) prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules issued thereunder and in terms of Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- 2) The audited consolidated financial results for the quarter and year ended 31-03-2025 have been reviewed by the Audit Committee of the Board and approved by the Board of Directors of the Company at their meetings held on 28-05-2025.
- 3) The audited consolidated financial results of the Group for the quarter and year ended 31-03-2025, have been audited by the statutory auditors and they have issued an unmodified audit report on the same. The audit report of the statutory auditors is being filed with the National Stock Exchange of India Limited ('NSE') and BSE Limited ('BSE') and is also available on the Company's website.
- 4) The consolidated figures for the quarter ended 31-03-2025 and 31-03-2024 as reported in these audited consolidated financial results are the balancing figures between consolidated audited figures in respect of the full financial years and the published unaudited year to date consolidated figures up to the third quarter of the previous financial year. Also, the consolidated figures up to the end of the third quarter of the previous financial year had only been reviewed and not subjected to audit.
- 5) The audited consolidated financial results for the quarter and year ended 31-03-2025 includes financial results of the following subsidiaries/step-down subsidiaries:

S.No	Name of the entity	Country	Relationship
1	NATCO Pharma Inc.	United States of America	Wholly owned Subsidiary
2	NATCO Pharma USA LLC	United States of America	Step-down Subsidiary
3	Time Cap Overseas Limited	Mauritius	Wholly owned Subsidiary
4	NatcoFarma do Brasil Ltda.	Brazil	Step-down Subsidiary
5	NATCO Pharma (Canada) Inc.	Canada	Wholly owned Subsidiary
6	NATCO Pharma Asia Pte. Ltd.	Singapore	Wholly owned Subsidiary
7	NATCO Pharma Australia PTY Ltd.	Australia	Wholly owned Subsidiary
8	NATCO Lifesciences Philippines Inc.	Philippines	Wholly owned Subsidiary
9	NATCO Pharma UK Limited (w.e.f. 04-09-2023)	United Kingdom	Wholly owned Subsidiary
10	PT.NATCO Lotus Farma (w.e.f. 28-08-2023)	Indonesia	Subsidiary
11	NATCO Pharma Colombia S.A.S. (w.e.f. 15-08-2023)	Colombia	Wholly owned Subsidiary

6) The audited standalone financial results, for the quarter and year ended 31-03-2025 can be viewed on the website of the Company, NSE and BSE at www.natcopharma.co.in, www.nseindia.com, and www.bseindia.com respectively. Information of audited standalone financial results of the Company in terms of Regulation 47(1)(b) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 is as under:

				(₹ in millions)
		Quarter ended		Year	ended
Particulars	31-03-2025	31-12-2024	31-03-2024	31-03-2025	31-03-2024
i u doularo	Audited (Refer	Unaudited	Audited	Audited	Audited
	note 4)		(Refer note 4)		
Total income	12,195	5,756	10,007	44,158	36,736
Profit before tax	5,208	1,503	4,325	22,260	15,553
Net profit for the period/ year	4,281	1,249	3,491	18,504	13,066
Total comprehensive income for the period/ year	4,049	1,403	3,473	18,491	13,142

7) During the quarter and year ended 31 March 2025, the Group has recognised an impairment loss of ₹ 500 million on account of impairment of property, plant and equipment of Agro chemical segment.

8) The Board of Directors at their meeting held on 12-02-2025 had approved an interim dividend of ₹ 1.5/- per equity share of ₹ 2 each for the quarter ended 31-12-2024. An interim dividend of ₹ 3 /- per equity share of ₹ 2 each for the quarter ended 30-06-2024 and an interim dividend of ₹ 1.5 /- per equity share of ₹ 2 each for the quarter ended 30-09-2024 was approved by Board of Directors at their meetings held on 12-08-2024 and 12-11-2024 respectively. The total dividend for the financial year ended 31-03-2025 works out to ₹ 6/- per equity share on equity shares of ₹ 2 each.

By order of the Board For NATCO Pharma Limited

V C Nannapaneni NATCI Chairman & Managing Director (DIN: 00183315)

Place: Hyderabad Date: 28 May 2025



Regd. Office: Natco House, Road No. 2, Banjara Hills, Hyderabad, Telangana - 500 034 Phone: +91-40-2354 7532, Website : www.natcopharma.co.in, CIN: L24230TG1981PLC003201

STATEMENT OF STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31-03-2025

S.No.	. Particulars Quarter ended				millions except per share dat Year ended		
		31-03-2025	31-12-2024	31-03-2024	31-03-2025	31-03-2024	
		Audited (Refer note 4)	Unaudited	Audited (Refer note 4)	Audited	Audited	
	Income						
1	Revenue from operations	11,574	4,076	9,648	40,945	35,689	
2	Other income	621	1,680	359	3,213	1,047	
3	Total income (1+2)	12,195	5,756	10,007	44,158	36,736	
4	Expenses						
	Cost of materials consumed	1,690	727	1,276	5,362	5,225	
	Purchases of stock-in-trade	97	148	80	455	348	
	Changes in inventories of finished goods, work-in-progress and stock-in-trade	429	(172)	(297)	116	172	
	Employee benefits expense	1,387	1,236	1,250	5,153	4,549	
	Finance costs	88	34	Self Contraction of the	196	145	
	Depreciation, amortisation and impairment expense (refer note 7 below)	937	437	516	2,200	1,719	
	Other expenses	2,359	1,843	2,812	8,416	9,02	
	Total expenses	6,987	4,253	5,682	21,898	21,183	
5	Profit before tax for the period/ year (3-4)	5,208	1,503	4,325	22,260	15,55	
6	Tax expense						
°	(i) Current tax	994	279	836	4.075	2,84	
	(ii) Deferred tax	(67)	(25)		(319)	(36	
	Total tax expense	927	254	834	3,756	2,48	
7	Profit for the period/ year (5-6)	4,281	1,249	3,491	18,504	13,06	
8	Other comprehensive income/ (loss) (net of tax)						
	Items that will not be reclassified to profit or loss:						
	Remeasurement of defined benefit liability/(asset)	(78)	-	(20)	(78)	(20	
	Tax on remeasurement of defined benefit liability/(asset)	27	-	7	27		
	Fair value changes in Equity investments through OCI	(212)	180	(7)	44	9	
	Tax impact of Fair value changes in Equity investments through OCI	31	(26)		(6)	(1	
	Other comprehensive income/ (loss) for the period/ year, net of tax	(232)	154	(18)	(13)	7	
9	Total comprehensive income for the period/ year (7+8)	4,049	1,403	3,473	18,491	13,14	
	Paid-up equity share capital (Face value of ₹2 each)	358	358	358	358	35	
	Other equity				72,981	55,56	
12	Earnings per share (not annualised for the quarters) (Face value of ₹2 each)						
	Basic (in ₹)	23.90	6.97	19.49	103.31	72.7	
	Diluted (in ₹)	23.90	6.97	19.49	103.31	72.7	

See accompanying notes to the audited standalone financial results.

o pharmarta NATCO Continued..



tandalone Balance Sheet:		(₹ in million
	As at	As at
	31-03-2025	31-03-2024
	(Audited)	(Audited)
Assets		
(1) Non-current assets		
(a) Property, plant and equipment	24,096	22,73
(b) Capital work-in-progress	2,253	1,3
(c) Other intangible assets	1,072	1
(d) Investment in subsidiaries	4,904	4,8
(e) Financial assets		1.
(i) Investments	747	g
(ii) Loans	5	
(iii) Other financial assets	1,815	4
(f) Deferred tax assets, net	410	
(g) Non-current tax assets, net	27	2
(h) Other non-current assets	490	6
Total non-current assets	35,819	31.4
	00,010	01,
2) Current assets		
(a) Inventories	6,421	5,9
(b) Financial assets	0,121	0,0
(i) Investments	2,900	1,6
(i) Trade receivables	11,782	10.7
(iii) Cash and cash equivalents	112	10,7
(ii) Cash and Cash equivalents (iv) Bank balances other than (iii) above		0.1
	18,457	8,5
(v) Loans	94	
(vi) Other financial assets	4,130	4,4
(c) Other current assets	2,984	2,5
Total current assets	46,880	34,1
Total assets	82,699	65,5
EQUITY AND LIABILITIES		
(1) Equity		
(a) Equity share capital	358	3
(b) Other equity	72,981	55.5
Total equity	73,339	55,9
2) Liabilities		
(A) Non-current liabilities		
(a) Financial liabilities		
(ia) Lease liabilities	12	
(ii) Other financial liabilities	46	
(h) Other mancial habilities (b) Provisions		-
Total non-current liabilities	656 714	7
	/14	/
(B) Current liabilities		
(a) Financial liabilities		
(i) Borrowings	2,731	3,6
(ia) Lease liabilities	3	
(ii) Trade payables		
Total outstanding duca of misra anterprises and small anterprises, and	176	
-Total outstanding dues of micro enterprises and small enterprises; and		
-Total outstanding dues of creditors other than micro enterprises		1,7
	2,075	
-Total outstanding dues of creditors other than micro enterprises	2,075 1,119	Ś
-Total outstanding dues of creditors other than micro enterprises and small enterprises		
-Total outstanding dues of creditors other than micro enterprises and small enterprises (iii) Other financial liabilities	1,119	1,0
-Total outstanding dues of creditors other than micro enterprises and small enterprises (iii) Other financial liabilities (b) Other current liabilities (c) Provisions	1,119 985	1,(1,(
-Total outstanding dues of creditors other than micro enterprises and small enterprises (iii) Other financial liabilities (b) Other current liabilities	1,119 985 779	1,(1,(1,(8,8
-Total outstanding dues of creditors other than micro enterprises and small enterprises (iii) Other financial liabilities (b) Other current liabilities (c) Provisions (d) Current tax liabilities (net)	1,119 985 779 778	1,(1,(
-Total outstanding dues of creditors other than micro enterprises and small enterprises (iii) Other financial liabilities (b) Other current liabilities (c) Provisions (d) Current tax liabilities (net) Total current liabilities	1,119 985 779 778 8,646	1,(1,(;

Pharma NATCO

NA



Standalone Statement of Cash Flows:

(₹ in millions)

ubjustments for insnec costs 2.200 1,7,7 insnec costs 108 1,7,7 insnec costs 108 1,7,7 insnec costs 108 1,7,7 insnec costs 108 1,7,7 insnec costs 100 1,7,7 insnec costs 1,7,7 1,7,7 insnec costs 1,10,7 1,11 insnec costs 1,10,20 1,11 insnec costs 1,10,20 1,12 insnec costs 1,10,20 1,12 insnec costs 1,10,20 1,12 insnec costs 1,10,20 1,12 insnec costs 1,10,20 1,17 increase in trade recoisvalos<	Standalone Statement of Cash Flows:	(₹ in millions)		
charter (Audited) (Audited) zash flows from operating activities on balable tax for the year digatments for increase in tories and impairment expenses increase in contrastic or and impairment expenses (1,701) 2,200 15,50 and extrastic or increase in a contrastic receivables and other financial assets, net (2,101) (2,100) 17,71 and extra written dif labilities written back (4 (gan)/ Loss and/or progress written off labilities written back (4 (gan)/ Loss and/or progress, plant and equipment (2 (gan)/ Loss or early ined/or magnetic written dicroms on equity ined/or magnetic written dicroms on equity ined/or magnetic written dicroms on equity ined/or magnetic written indic papables (2 (gan)/ Loss or early ined/or written is (2 (gan)/ Loss or early ined/or written (2 (gan)/ Loss or early ined/or written (2 (gan)/ Loss or early ined/ Loss or early ined/or written (2 (gan)/ Loss or early ined/or written (2 (gan)/ Loss or early ined/ Loss or (2 (gan)/ Loss or early ine		Year ended		
ash flows from operating activities 22,200 15,5 roft before lax for the year 22,200 15,7 ingetectation, amorbisation and impairment expenses 2,200 17,7 ingetectation, amorbisation and expenses 10,000 10,000 ingetectation, amorbisation, amorbisati		31-03-2025	31-03-2024	
trofit before lax for the year 22.200 15.5 bepreciation, amorisation and impairment expenses 2.200 17.7 instance costs 196 17.9 terrest income (1,701) (8) voision of reversal) of credit loss allowance on trade receivables and other financial assets, net (1,701) (8) ad debts writen off 30 30 ad debts writen off 30 30 bill (gain) / Loss on sale of property, plant and equipment (1,701) (8) bill of diminution in value of investment (1,701) (8) transale in tords exchange loss? (add), net (8) (2,206 transale in tords exchange loss? (add), net (8) (8) transale in tords exchange loss? (add), net (8) (8) transale in tords exchange loss? (add), net (8) (8) transale in tords exchange loss? (add), net (8) (8) transale in tords exchange loss? (add), net (8) (8) transale in tords exchange loss? (add), net (8) (8) transale in tords exchange loss? (add) (4) (4) transale in tords exchange loss? (3) (6) transale in tords exchange loss? (4) (4) transale in tords exchange loss? (4)		(Audited)	(Audited)	
trofit before lax for the year 22.200 15.5 bepreciation, amorisation and impairment expenses 2.200 17.7 instance costs 196 17.9 terrest income (1,701) (8) voision of reversal) of credit loss allowance on trade receivables and other financial assets, net (1,701) (8) ad debts writen off 30 30 ad debts writen off 30 30 bill (gain) / Loss on sale of property, plant and equipment (1,701) (8) bill of diminution in value of investment (1,701) (8) transale in tords exchange loss? (add), net (8) (2,206 transale in tords exchange loss? (add), net (8) (8) transale in tords exchange loss? (add), net (8) (8) transale in tords exchange loss? (add), net (8) (8) transale in tords exchange loss? (add), net (8) (8) transale in tords exchange loss? (add), net (8) (8) transale in tords exchange loss? (add), net (8) (8) transale in tords exchange loss? (add) (4) (4) transale in tords exchange loss? (3) (6) transale in tords exchange loss? (4) (4) transale in tords exchange loss? (4)	Cash flows from operating activities			
ubjustments for insnec costs 2.200 1,7,7 insnec costs 108 1,7,7 insnec costs 108 1,7,7 insnec costs 108 1,7,7 insnec costs 108 1,7,7 insnec costs 100 1,7,7 insnec costs 1,7,7 1,7,7 insnec costs 1,10,7 1,11 insnec costs 1,10,20 1,11 insnec costs 1,10,20 1,12 insnec costs 1,10,20 1,12 insnec costs 1,10,20 1,12 insnec costs 1,10,20 1,12 insnec costs 1,10,20 1,17 increase in trade recoisvalos<		22 260	15,553	
Percentation, amortisation and impairment expenses index costs transe costs transe costs transe costs transe costs and debts written off (7, 10, 10, 10, 10, 10, 10, 10, 10, 10, 10		12,200	10,000	
infance costs 196 1. interset income 1.7.01 (1.7.01) Yousion or (reversa) of credit loss allowance on trade receivables and other financial assets, net apatal work-in-progress withen off 3.0 apatal work-in-progress withen off 3.0 3.0 apatal work-in-progress withen off 3.0 3.0 apatal work-in-progress withen off 3.0 3.0 bit distities withen back (3.1) 3.0 low and a off interset income (1.4) 3.0 Worked in come on equity investment tail value through other comprehensive income (1.2) 2.0 Worked in come on equity investment tail value through other comprehensive income (2.1) 2.0 Worked in come assets in other financial assets (3.3) (6.0) mease in back (regress) (3.6) (1.0.2) (1.0.2) mease in back (regress) (3.6) (1.0.2) (1.0.2) (2.9) mease in other inancial labitities (3.6) (1.0.2) (2.9) mease in other inancial labitities (4.0.37) (2.9) (2.9) (2.9) (2.9) (2.9) (2.9)<		2 200	1,719	
therest income (1,701) (8) vision of (reveal) of cradit loss allowance on trade receivables and other financial assets, net (2) 2 aid adbits written off 30 30 jabilities written back (3) 30 id (gin)/ Loss on sale of property, plant and equipment (3) 30 Profit/ loss on sale of property, plant and equipment (3) 30 vision of drinking mexhange loss (gan), net (2) 2 parating profit hore working capital hanges (4) 2 vision of drinking mexhange loss (gan), net (6) 1 parating profit hore working capital hanges (4) 2 increase in theore working capital hanges (4) 2 increase in theore working capital hanges (4) 1 increase in theore working capital hanges (4) 1 increase in theore working capital hanges (4) 1 increase in trade payables (4) 2 Decrease in receivables (6) 1 increase in trade nagating activities (6) 1 transfer do francial labilities (6) 1 capa do investing activities (A) (4) 2 transfer do francial assets (3) 1 increase in othere invest			145	
trovision of reversal) of credit loss allowance on trade receivables and other financial assets, net 122 2 addets written off 30 aptail work-in-progress written off 30 abilities written back (5) let (gain)/Loss on sale of property, plant and equipment (70) Profiviol son sale of investment tair value through other comprehensive income (21) Violend income on equity investment tair value through other comprehensive income (21) transles for writing capital changes (22,658 increase in that encome (44) operating profit before working capital changes (28) increase in that encome capital changes (20) increase in tain de capital assets (30) operating decrease in intervintories (452) operated in tain encoulable (452) operated from operating activities (30) operated from operating activities (30) operated from operating activities (40) uncrea			(853	
aid debx written off 11 11 jabilities written back (5) ide (gain)/Loss on sale of property, plant and equipment (67) Profif)/loss on sale of investments (14) jabilities written back (7) investment af fair value through other comprehensive income (21) voision of dimitution in value of investment (12) inrealised foreign exchange loss(gain), net (8) pertaing profit horeor working capital changes (13) increase) (14) increase in intrade receivables (13) increase in intrade receivables (13) increase in trade receivables (10) increase in trade receivables (10) increase in intrade receivables (10) increase in intrade receivables (10) increase in due financial isabilities (20) Decrease/ increase in after financial isabilities (20) increase in due financial isabilities (20) increase in after financial isabilities (20) increase in due financial isabilities (A			227	
Spinil work-in-progress written off 30 Labilities written back (5) Let (gain)/ Loss on sale of property, plant and equipment (6) Profil/ loss on sale of investment at fair value through other comprehensive income (21) Violend income on equity investment at fair value through other comprehensive income (21) Violend income on equity investment at fair value through other comprehensive income (21) Pperating profit before working capital changes (28) Increase in trade exchange loss(gain), net (8) Increase in trade rease in a fair value states (33) Increase in trade rease in trade rease is (38) Decrease in trade rease in trade rease in state states (38) Creases in trade rease in a fair value states (34) Decrease in provisions (34) Decrease in provisions (34) State generated from operating activities (40) Varbades of property, plant and equipment (40) Varbades of prava	Bad debts written off		51	
Jabilites writen back (5) Heighip/Loss on sale of property, plant and equipment (74) Journates income Profiti/Joss on sale of investments Jurnalised foreign exchange loss(gain), net Heighip/Loss on gale (sinvestment at fair value through other comprehensive income Vision of drininution in value of prostream Heighip/Loss on gale of investment Heighip/Loss of investment Heighip/Loss of investment Heighip/Loss of investments Heighip/Loss	Capital work-in-progress written off		-	
let gain/Lose on sale of property, plant and equipment (870) (570) (580) (580) (671) (580) (671) (580) (671) (580) (671) (580) (671) (580) (671) (580) (671) (580) (671) (580) (672) (77) (77) (77) (77) (77) (77) (77) (Liabilities written back		(3	
Profiv Diss on sale of investments Vided nicome on equity investment at fair value through other comprehensive income Vided nicome on equity investment at fair value through other comprehensive income Vided nicome on equity investment at fair value through other comprehensive income Vided nicome on equity investment at fair value through other comprehensive income Vided nicome on equity investment at fair value through other comprehensive income Vided nicome on equity investment at fair value through other comprehensive income Vided nicome on equity investment at fair value through other comprehensive income Vided nicome investment at fair value through other comprehensive income Vided nicome investment at fair value through other comprehensive income Vided nicome investment at fair value through other comprehensive income Vided nicome investment at fair value through other comprehensive income Vided nicome investment at fair value through other comprehensive income Vided nicome investment at fair value through other comprehensive income Vided nicome investment at fair value through other comprehensive income Vided nicome investment at fair value through other comprehensive income Vided nicome investment at fair value through other comprehensive income Vided nicome investments Vided nicome investments Vided nicome investments Vided nicome investment at fair value through other comprehensive income Vided nicome investment at the equipment Vided nicome investments Vided nicome investments Vided nicome investment at the equipment Vides Vided Vided Video Vided Video V	Net (gain)/ Loss on sale of property, plant and equipment		17	
Juarantee Income Juarantee Income Juarantee Income Juarantee Income (21) Juarantee Income (21) Juarantee Income on equity investment 1/// 1/// Prealied forting capital changes Capter Stands S	(Profit)/ loss on sale of investments		9	
bixedend income on equity investment at fair value through other comprehensive income investion of dimuton in value of investment investion of dimuton in value of investment investion of dimuton in value of investment investion of dimuton investing activities investing activities investion of dimut	Guarantee income	-	(2	
trovision for diminution in value of investment increase in trade parkange lossing (apin), net beranges in working capital changes banges in working capital increase in trade parkange lossing increase in trade parkange becrease in trade parkange crease in trade par	Dividend income on equity investment at fair value through other comprehensive income	(21)	(3	
Decreating profit before working capital changes 22,056 17,00 Indreasely decrease in inventories (452) 1 Increasely decrease in other financial assets (33) (34) Increase in date reselvables (35) (36) Decrease/ increase in other financial assets (36) (36) Decrease/ increase in other financial isbilities (361) (36) Decrease/ increase in other financial isbilities (361) (34) Decrease/ increase in other financial isbilities (361) (34) Decrease/ increase in other financial isbilities (361) (34) Decrease/ increase in other financial isbilities (36) (34) Decrease/ increase in other financial isbilities (36) (34) Decrease/ increase in other financial isbilities (36) (34) Concests from secting activities (A) (34) (34) Cash flows from investing activities (A) (35) (35) Cash flows from investing activities (A) (35) (35) Cash flows from investing activities (A) (40) (35) Cash flows from investing activities (A) (40) (40) Cash flows from investing activities (36) (44) Cash flows from investing activities (36) (44)	Provision for diminution in value of investment	-	210	
Decreating profit before working capital changes 22,056 17,00 Indrease in working capital (452) 1 Increase in the receivable (1,027) (2,966) Increase in table receivables (3) (3) Increase in table reservables (452) (1,027) Decrease/increase in other financial labilities (452) (1,027) Decrease/increase in other financial labilities (31) (31) Decrease/increase in other financial labilities (31) (31) Decrease/increase in other financial labilities (34) (10) Decrease/increase in other financial labilities (34) (34) Decrease/increase in other financial labilities (34) (34) Decrease/increase (35) (16) Decrease/increase (34) (34) Decrease/increase (35) (16) Decrease/increase (36)	Unrealised foreign exchange loss/(gain), net	(8)	(8)	
Thanges in working capital Improve the intervention of the provision of the provisis of the the provision of the provision of the provis	Operating profit before working capital changes		17,062	
ncrease in trade receivables (1132) (2.95 (33) (339) (66 (381) (389) (66 (381) (108)	Changes in working capital			
ncrease in trade receivables (1.0.22) (2.9.1) ncreases in other financial assets (3) (3) ncreases in other financial assets (3) (3) ncreases in intrade payables (3) (3) Decrease/increase in other financial liabilities (10) (11) Decrease/increase in other financial liabilities (10) (11) Decrease/increase in other financial assets (3) (6) Come-taxes paid, net of refund (54) (14) Cash flows from investing activities (2,6) (14) come-taxes paid, net of refund (3,446) (2,50) Cash flows from investing activities (3) (3,3) rocease from sale of property, plant and equipment (90) (3,3) rocease from sale of property, plant and equipment (85) (7,7) rocease from sale of investments (15,62) (14) rocease from sale of investments (15,7) (1,44) rocease from sale of investments (2,517) (1,42)	(Increase)/ decrease in inventories	(452)	191	
Increase) decrease in other financial assets increase in other assets increase in other assets increase in other financial assets increase in other financial labilities increase in other financial assets increase in other financial assets increase in other financial set integration increases of property, plant and equipment increase of property, plant and equipment increase of investments increase of other set of endored shares increase of experise of the assets increase of experise of the assets increase of experise of the assets increase of experise of the asset increase of investments increase of experise of the asset increase of investments increase of experise of the asset in a state benerse of experise of the asset in the asset is including transaction costs and taxes on buy-back if (taxpr) infrance activities if the asset in a state benerse including transaction costs and taxes on buy-back if (taxpr) infrance activities (tay) if the asset in investing activities (tere note below) if the interest payment of lease liabilities (refer note below) if the asset in investing activities (tere note below) if the cash and cash equivalents as a	Increase in trade receivables		(2,921	
increase in other assets (38) (68) Decrease/increase in provisions (38) (37) Decrease/increase in provisions (38) (31) Decrease/increase in other financial liabilities (36) (106) Decrease/increase in other financial liabilities (34) (34) Carbone-taxes provisions (34) (34) Carbone-taxes provisions (34) (34) Carbone-taxes provisions (34) (34) Carbone-taxes provisions (40) (34) Carbone-taxes provisions (40) (40) Carbone-taxes property, plant and equipment (40) (40) Croceds from sale of property, plant and equipment (40) (40) Croceds from sale of investments (40) (40) Croceds from sale of investments (25,17) (14) Opeosits of the an with banks (25,17) (14) Opeosits of the an with banks (25,17) (14) Opeosits of the an with banks (26,17) (14)	(Increase)/ decrease in other financial assets		7	
increase in rotation payables 1427 Decrease/increase in order financial liabilities (381) Decrease/increase in other financial liabilities (381) Decrease/increase in other financial liabilities (384) Cash generated from operating activities (A) 16,620 Data file (4,037) Cash flows from investing activities (4,037) Creaceds from sale of property, plant and equipment (4,037) Vicceeds from sale of property, plant and equipment (4,037) Vicceeds from sale of property, plant and equipment (4,037) Vicceeds from sale of property, plant and equipment (4,037) Vicceeds from sale of property, plant and equipment (4,037) Vicceeds from sale of property, plant and equipment (4,037) Vicceeds from sale of property, plant and equipment (4,037) Vicceeds from sale of property, plant and equipment (5,05) Vicceeds from sale of property, plant and equipment (5,05) Vicceeds from sale of property, plant and equipment (5,05) Vicceeds from sale of property activities (4,07) Vicceeds from sale of property, plant and	Increase in other assets		(603	
Decrease) increase in provisions (381) (481) Decrease) increase in other financial liabilities (40) Decrease in other decipient (40, 037) Unchase of investing activities (41) Decrease in other size of property, plant and equipment (40, 037) (41, 037) Decrease in other size of unquoted shares (41, 047) Decrease form sale of investments (41, 047) Decrease form sale of investments (41, 047) Decrease of unquoted shares (43, 047) Decrease of unquoted shares (44, 047) Decrease of unquote	Increase in trade payables		11	
Decrease/increase in other financial liabilities Decrease/increase index for liabilities Decrease in other liabilities (refer note below) Decrease in other liabilities (refer note below) Decrease in other liabilities (refer note below) Decrease in other liabilities (References) Decrease in other liabilities (References) Decrease in other liabilities (refer note below) Decrease in other liabilities (References) Decrease in cash and cash equivalents as at the end of the year Decrease in cash and cash equivalents as at the end of the year Decrease in other liabilities (References) Decrease in other liabilities in accordance with Ind AS 7: Decrease in other liabilities (References) Decrease	(Decrease)/ increase in provisions		696	
becrease in other liabilities (54) (14) Sash generated from operating activities 20,066 14,4 Come-taxes paid, net of refund (3,446) (2,252) Varchase of property, plant and equipment (4,037) (3,346) varchase of property, plant and equipment (4,037) (3,346) varchase of property, plant and equipment (4,037) (3,347) varchase of property, plant and equipment (4,037) (3,347) varchase of unanybo others (1,043) (4) (4) varchase of unquoted shares (3,01) (1,043) (4) varchase of unquoted shares (3,01) (1,043) (4) (4,037) varchase of unquoted shares (2,517) (1,44) (4,037) (4,477) varchase of unquoted shares (2,257) (1,44) (4,177) (4,243) (9,66) varchase of unquoted shares (3,01) (1,248) (4,477) (4,243) (9,66) varchase of unquoted shares (3,248) (2,77) (4,4437) (4,243)	(Decrease)/ increase in other financial liabilities		191	
Dash generated from operating activities 20,066 14,44 ncome-taxes paid, net of refund (3,446) (2,52) tet cash generated from operating activities (A) 16,620 111,91 Stash flows from investing activities (4,037) (3,34) functase of property, plant and equipment (4,037) (3,34) ruccausition of intangible assets (1,043) (7,04) vestiments in subsidiaries (1,043) (4) rocceeds from sale of investments (4,057) (4,057) vestiments in subsidiaries (2,517) (1,44) vachase of investments (2,517) (1,44) vachase of investments (2,517) (1,44) veposits with banks (1,704) (9,00) tedemption of deposits other than with banks (3,44) (2,17) tedemption of deposits other than with banks (4,77) (4,403) tedemption of deposits other than with banks (2,517) (1,44) tedemption of deposits other than with banks (2,517) (4,477) tedemption of deposits other than with banks (2,62) (2,00) tel (repayment of bank deposits (8,82)	Decrease in other liabilities		(150)	
ncome-taxes paid, net of refund let cash generated from operating activities (A) 2ash flows from investing activities (4,037)	Cash generated from operating activities	`	14,484	
let cash generated from operating activities (A) 16,620 11,90 2ash flows from investing activities (4,037) (3,34 Yurchase of property, plant and equipment (4,037) (3,34 Cocceds from sile of property, plant and equipment (4,037) (3,34 Cocceds from sile of property, plant and equipment (4,037) (3,34 Cocceds from sile of property, plant and equipment (4,037) (3,34 Cocceds from sile of investments (1,043) (2 Verstments in subsidiaries (3,0) (2,517) (1,44 Vicedes from sile of investments (2,517) (1,44 (4,07) (3,04 Virturbase of investments (2,517) (1,44 (4,07) (4,07) (1,078) (1,7,74) (4,477) (4,07) (4,07) (4,07) (4,07) (4,07) (4,07) (4,07) (4,07) (4,07) (4,07) (4,477) (4,07) (4,477) (4,477) (4,477) (4,477) (4,477) (4,477) (4,07) (4,477) (4,07) (4,07) (4,07) (5,07) (1,44,479) (9,66) (1,07,8) (1,77) (7,7) (7,7) (7,7) <td></td> <td></td> <td>(2,520)</td>			(2,520)	
ash flows from investing activities 				
Purchase of property, plant and equipment (4,037) (3,34 Proceeds from sale of property, plant and equipment 950 3 Proceeds from sale of property, plant and equipment (85) (7 Repayment of loans by others (85) (7 Repayment of loans by others (85) (7 Vurchase of investments 1,556 1,33 dyarchase of unquoted shares (30) (18,704) (9,00 Redemption of bank deposits (18,704) (9,00 (18,704) (9,00 Redemption of bank deposits (18,704) (9,00 (14,439) (9,00 Redemption of bank deposits (18,704) (9,00 (14,439) (9,00 Redemption of baposits other than with banks 3,848 2,77 (4,007) (4,007) (4,007) (4,007) (4,007) (4,007) (4,007) (4,007) (4,007) (4,007) (14,439) (9,60 (14,439) (9,60 (14,439) (9,60 (17,70) (17,70) (17,70) (17,70) (17,70) (17,70) (17,70) (17,70) (17,70) (17,70) (17,70) (17,70) (17,70) <td< td=""><td></td><td>10,020</td><td>11,004</td></td<>		10,020	11,004	
Proceeds from sale of property, plant and equipment 990 1 kcquisition of intangible assets (1,043) (2 kcquisition of intangible assets (2,517) (1,44 kcquisition of bank deposits (1,8,704) (8,02) ktedemption of deposits other than with banks (2,4,77) (4,06) kted cash used in investing activities (1,4,439) (9,60) kte (repayment of)/ proceeds short-term borrowings (refer note below) (1,078) (1,177) vidends paid (1,078) (1,177) (1,77) vidends paid (1,078) (1,177) (2,2,37) <	Cash flows from investing activities			
ucquisition of intangible assets (1,043) (2 rvestments in subsidiaries (65) (7 typayment of loans by others (4) (4) typayment of loans by others (30) (30) vurchase of investments (2,517) (1,44) byposits with banks (1,704) (9,00) Redemption of bank deposits (8,825) 4,55 terest received (1,437) (4,00) bydend received (1,704) (9,00) terest received (1,4439) (2,517) beposits other than with banks (3,848) 2,77 beposits other than with banks (4,477) (4,00) tet cash used in investing activities (B) (1,078) (1,70,80) cash flows from financing activities (1,078) (1,77) inance cost paid (1,078) (1,77) trincipal and interest payment of lease liabilities (refer note below) (2,124) (2,124) bividends paid (1,078) (1,77) (1,77) tinance cost paid (117) (17) (17) tinance cost equivalents as ath te ed of the year 55	Purchase of property, plant and equipment	(4,037)	(3,342)	
nvestments in subsidiaries (65) (72 Repayment of loans by others (4) Yonceds from sale of investments (30) Uurchase of investments (2,517) Upposits with banks (2,517) Repayment of bank deposits 8,825 Reposits with banks (18,704) Reposits with banks (14,477) Vidend received 1,248 Vidend received 21 Vidend received (14,477) Vidend received (14,477) Vidend received (14,477) Vidend received (14,439) Vidend received (17,7) Vidend received (10,78) Vidend received (17,7) Vidend received (17,7) Vidend received (17	Proceeds from sale of property, plant and equipment	950	20	
Repayment of loans by others (4) troceeds from sale of investments 1,566 Varchase of investments (2,517) Purchase of investments (2,517) Varchase of investments (18,704) Verchase of investments (2,517) Varchase of investments (2,517) Varchase of investments (18,704) Verchase of investments (2,517) Varchase of investments (2,517) Varchase of investments (14,470) Verchase of investments (1,477) Varchase of investing activities (B) (14,439) Vare of provestors of other than with banks (4,477) Vare of provestors investing activities (B) (14,439) Vare of provestors and taxes on buy-back (1,477) Vare of provestors and interest payment of lease liabilities (refer note below) (1,078) Virincipal and interest payment of lease liabilities (refer note below) (1,17) Vart of bash and cash equivalents (A+B+C) 57 Cash and cash equivalents as at the end of the year 112 Vare to borrowings 3,632 Vare of provends a diabilities in accordance with Ind AS 7: (17) Vare of provends a diabilities in accordance with Ind AS 7: (17) Vare to borrowings 3,632 1,55 <td>Acquisition of intangible assets</td> <td>(1,043)</td> <td>(24)</td>	Acquisition of intangible assets	(1,043)	(24)	
Troceeds from sale of investments turchase of investments turchase of investments turchase of investments terest received turchase of investments terest received teresteret terest rece	Investments in subsidiaries	(85)	(726)	
dvance for purchase of unquoted shares (30) urchase of investments (2,517) Poposits with banks (18,704) Redemption of bank deposits 8,825 Interest received 1,248 Widend received 1,248 Redemption of deposits other than with banks 3,848 Deposits with investing activities (B) (14,439) Cash flows from financing activities (14,439) ayment on buy-back of shares, including transaction costs and taxes on buy-back - let (repayment of)/ proceeds short-term borrowings (refer note below) (1820) Dividends paid (1,078) (1,078) (1,77) (1,078) (1,77) (1,078) (1,77) (1,078) (1,77) (1,078) (1,77) (1,078) (1,77) (1,078) (1,77) (1,170) (1 Videt cash used in financing activities (C) 55 Let cash used in financing activities (C) (2,124) Let cash used in financing activities (C) (1,27) Let cash used in financing activities (C) 57 Let increase/ (decrea	Repayment of loans by others	(4)	12	
Purchase of investments (2, 517) (1, 44) beposits with banks (18, 704) (9, 06) sedemption of bank deposits 8, 825 4, 55 Interest received 1,248 44 Dividend received 2,1 dedemption of deposits other than with banks 3,848 2,77 Deposits other than with banks 3,848 2,77 Deposits other than with banks (4,477) (4,06) Deposits other than with banks (14,439) (9,66) Cash flows from financing activities (14,439) (9,66) Cash flows from financing activities (10,778) (1,778) Vidends paid (10,778) (1,778) (1,777) (11,078) (1,777) (1,273) (1,177) Vidends paid (137) (1,177) (1,177) Vincipal and interest payment of lease liabilities (refer note below) (137) (1,177) Videt cash used in financing activities (C) (2,124) (2,33) Let tancrease/ (decrease) in cash and cash equivalents (A+B+C) 57 (1 Cash and cash equivalents as at the ed of the year 55 50 Date in financing activities (C) (892) 2,00 Cash and cash equivalents as at the ed of the year 55	Proceeds from sale of investments	1,566	1,334	
Deposits with banks(11,704)(19,00Redemption of bank deposits8,8254,55Interest received1,24844Vidend received21Redemption of deposits other than with banks3,8482,77Upposits other than with banks3,8482,77Veposits other than with banks3,8482,77Vet cash used in investing activities (B)(14,439)(9,60Verification of / proceeds short-term borrowings (refer note below)(10,078)(1,77Vincipal and interest payment of lease liabilities (refer note below)(11,77(11,77Vet cash used in financing activities (C)(2,124)(2,337Vet increase/ (decrease) in cash and cash equivalents (A+B+C)57(11,27Cash and cash equivalents as at the end of the year55112Vet increase3,6321,51,5Cash and cash equivalents as at the end of the year3,6321,5Vet increase3,	Advance for purchase of unquoted shares	(30)	-	
Redemption of bank deposits8,8254,53therest received1,24844Dividend received21tedemption of deposits other than with banks3,8482,77Deposits other than with banks(4,477)(4,05)Let cash used in investing activities(14,439)(9,66)Payment on buy-back of shares, including transaction costs and taxes on buy-back(14,439)(9,66)Cash flows from financing activities(892)2,00)Payment on buy-back of shares, including transaction costs and taxes on buy-back(10,78)(1,77)Cinance cost paid(1,078)(1,77)(1,177)Cinance cost paid(1,177)(1,177)(1,177)Principal and interest payment of lease liabilities (refer note below)(1,177)(1,177)Let cash used in financing activities (C)(2,124)(2,31)Let cash equivalents as at the beginning of the year55(1,23)Cash and cash equivalents as at the od of the year55(1,23)Let: Movement in borrowings and lease liabilities in accordance with Ind AS 7:(892)2,00Current borrowings(892)2,00(1,53)Depaing balance(892)2,00(1,53)Repayment of)/ Net proceeds from short-term borrowings(892)2,00Lease liabilities(2,731)3,6321,55Depaing balance(9)2,7313,6321,55Depaing balance29(1,77)(1,77)(1,77)Depaing balance29(1,77)(1,77) <td< td=""><td>Purchase of investments</td><td>(2,517)</td><td>(1,493)</td></td<>	Purchase of investments	(2,517)	(1,493)	
Interest received 1,248 44 Dividend received 21 Redemption of deposits other than with banks 3,848 2,77 Upposits other than with banks (4,477) (4,439) Uet cash used in investing activities (B) (14,439) (9,60 Cash flows from financing activities (14,439) (9,60 Payment on buy-back of shares, including transaction costs and taxes on buy-back (2,55 Let (repayment of)/ proceeds short-term borrowings (refer note below) (10,78) (1,70 Dividends paid (1,078) (1,77) (1 Principal and interest payment of lease liabilities (refer note below) (177) (1 Let cash used in financing activities (C) (2,124) (2,33) Let increase/ (decrease) in cash and cash equivalents (A+B+C) 57 (1 Cash and cash equivalents as at the end of the year 55 0 Cash and cash equivalents as at the end of the year 112 2 Cash and cash equivalents as at the end of the year 3,632 1,5 Chorems trib borrowings (892) 2,0 Corrent us borrowings and lease liabilities in accordance with Ind AS 7: 20 Current borrowings (892) 2,0 Con-cash items (Foreign exchange changes) (9) Con-cash it	Deposits with banks	(18,704)	(9,081)	
Dividend received 21 Redemption of deposits other than with banks 3,848 2,77 Deposits other than with banks (4,477) (4,05 Deposits other than with banks (14,439) (9,60 Cash flows from financing activities (14,439) (9,60 Dash flows from financing activities (14,439) (9,60 Cash flows from financing activities (10,78) (1,77) Dividends paid (1,078) (1,77) (1,77) Dividends paid (10,78) (1,77) (1,77) Dividends paid (137) (14 (14,77) (4,477) (4,477) Dividends paid (1,078) (1,778) (1,770) <td>Redemption of bank deposits</td> <td>8,825</td> <td>4,538</td>	Redemption of bank deposits	8,825	4,538	
Redemption of deposits other than with banks3,8482,77Deposits other than with banks(4,477)(4,05)Let cash used in investing activities (B)(14,439)(9,60)Cash flows from financing activities(14,439)(9,60)Payment on buy-back of shares, including transaction costs and taxes on buy-back-(2,53)Cash flows from financing activities(10,78)(1,70)Payment of/ proceeds short-term borrowings (refer note below)(10,78)(1,70)Dividends paid(1,078)(1,70)(1,70)Crincipal and interest payment of lease liabilities (refer note below)(137)(1,17)Principal and interest payment of lease liabilities (refer note below)(1,77)(1,17)Let cash used in financing activities (C)(2,124)(2,33)Let increase/ (decrease) in cash and cash equivalents (A+B+C)57(1,12)Cash and cash equivalents as at the end of the year11255Cash and cash equivalents as at the end of the year11255Current borrowings(892)2,00Dopening balance(892)2,00Repayment of/) Net proceeds from short-term borrowings(892)2,00Non-cash items (Foreign exchange changes)(9)(892)2,00Lease liabilities29(17)(17)(17)Dening balance29(17)(17)(17)Lease liabilities(17)(17)(17)(17)Lease liabilities(17)(17)(17)(17)Lease liabili	Interest received	1,248	480	
Deposits other than with banks (4,477) (4,000) Let cash used in investing activities (B) (14,439) (9,60) Cash flows from financing activities - (2,55) Payment on buy-back of shares, including transaction costs and taxes on buy-back - (2,55) Net (repayment of)/ proceeds short-term borrowings (refer note below) (10,078) (1,77) Dividends paid (1,078) (1,77) (1,77) Tinance cost paid (1,778) (1,77) (1,77) Tincipal and interest payment of lease liabilities (refer note below) (1,77) (1,77) (1,77) Let cash used in financing activities (C) (2,124) (2,124) (2,23) Let increase/ (decrease) in cash and cash equivalents (A+B+C) 57 (112) (112) Sash and cash equivalents as at the end of the year 112 (12) (12,124) (2,124) Opening balance 3,632 1,5 (1,53) (1,53) (1,53) (1,53) Repayment of)/ Net proceeds from short-term borrowings (892) 2,00 (1,72) (1,72) (1,72) Sober in borrowings (892) 2,00 (1,72) (1,72) <	Dividend received	21	3	
Let cash used in investing activities (B) (14,439) (9,6) Cash flows from financing activities (14,439) (9,6) Payment on buy-back of shares, including transaction costs and taxes on buy-back - (2,53) Let (repayment of)/ proceeds short-term borrowings (refer note below) (1,078) (1,778) Dividends paid (1,078) (1,078) (1,778) Trincipal and interest payment of lease liabilities (refer note below) (1177) (1 Let cash used in financing activities (C) (2,124) (2,23) Let increase/ (decrease) in cash and cash equivalents (A+B+C) 57 (1 Cash and cash equivalents as at the beginning of the year 55 (1 Cash and cash equivalents as at the end of the year 3,632 1,5 Current borrowings (892) 2,00 Opening balance 3,632 1,5 Repayment of)/ Net proceeds from short-term borrowings (892) 2,00 Non-cash items (Foreign exchange changes) (9) (17) Lease liabilities 29 29 29 Cash flow changes (17) (17) (17)	Redemption of deposits other than with banks	3,848	2,772	
Cash flows from financing activities (1,010000000000000000000000000000000000	Deposits other than with banks	(4,477)	(4,098)	
Cash flows from financing activities - (2,53) Yayment on buy-back of shares, including transaction costs and taxes on buy-back - (2,53) Vet (repayment of) proceeds short-term borrowings (refer note below) (1,078) (1,078) Dividends paid (1,078) (1,078) (1,077) Trincipal and interest payment of lease liabilities (refer note below) (1,177) (1 Vet cash used in financing activities (C) (2,124) (2,33) Vet increase/ (decrease) in cash and cash equivalents (A+B+C) 57 (1 Cash and cash equivalents as at the beginning of the year 55 0 Cash and cash equivalents as at the end of the year 112 4 Vote: Movement in borrowings 3,632 1,5 Opening balance 3,632 1,5 Repayment of)/ Net proceeds from short-term borrowings (892) 2,0 Non-cash items (Foreign exchange changes) (9) 2,731 3,6 Pening balance 29 29 29 29 Cash flow changes (17) (17) (17)	Net cash used in investing activities (B)	(14,439)	(9,605)	
Payment on buy-back of shares, including transaction costs and taxes on buy-back-(2,53)Net (repayment of)/ proceeds short-term borrowings (refer note below)(892)2,00Dividends paid(1,078)(1,70Grance cost paid(137)(14)Principal and interest payment of lease liabilities (refer note below)(17)(17)Net increase/ (decrease) in cash and cash equivalents (A+B+C)57(17)Cash and cash equivalents as at the beginning of the year55(12)Cash and cash equivalents as at the end of the year11255Cash and cash equivalents in accordance with Ind AS 7:(892)2,00Current borrowings(892)2,00(17)Opening balance3,6321,5(1,5)Repayment of)/ Net proceeds from short-term borrowings(9)(9)Lease liabilities27313,6Cash flow changes29(17)(17)Cash flow changes(17)(17)(17)				
Net (repayment of)/ proceeds short-term borrowings (refer note below)(892)2,00Dividends paid(1,078)(1,7078)Character cost paid(137)(14Principal and interest payment of lease liabilities (refer note below)(117)(117)Net cash used in financing activities (C)(2,124)(2,337)Net increase/ (decrease) in cash and cash equivalents (A+B+C)57(117)Cash and cash equivalents as at the beginning of the year55(112)Cash and cash equivalents as at the end of the year112(112)Note: Movement in borrowings and lease liabilities in accordance with Ind AS 7:3,6321,5Current borrowings(892)2,00(17)Opening balance(892)2,00(17)Lease liabilities(17)(110)(110)Lease liabilities29(110)(110)Cash flow changes(117)(110)(110)	Cash flows from financing activities			
Net (repayment of)/ proceeds short-term borrowings (refer note below)(892)2,00Dividends paid(1,078)(1,70(11,078)(1,70)(1,70)(11,08)(1,70)(1,70)(11,08)(1,70)(1,70)(11,08)(1,70)(1,70)(11,08)(1,70)(1,70)(11,08)(1,70)(1,70)(11,08)(1,70)(1,70)(11,08)(1,70)(1,70)(11,08)(1,70)(1,70)(11,08)(1,70)(1,70)(11,08)(1,70)(1,70)(11,08)	Payment on buy-back of shares, including transaction costs and taxes on buy-back		(2,537)	
inance cost paid (137) (14 Principal and interest payment of lease liabilities (refer note below) (17) (17) Let cash used in financing activities (C) (2,124) (2,33) Let increase/ (decrease) in cash and cash equivalents (A+B+C) 57 (17) Cash and cash equivalents as at the beginning of the year 55 0 Cash and cash equivalents as at the end of the year 112 12 Cash and cash equivalents as at the end of the year 3,632 1,5 Current borrowings (892) 2,0 Opening balance (9) 2,731 3,6 Repayment of)/ Net proceeds from short-term borrowings (9) 2,731 3,6 Lease liabilities 29 29 29 20 Cash flow changes (17) (12) 10 10	Net (repayment of)/ proceeds short-term borrowings (refer note below)	(892)	2,029	
Principal and interest payment of lease liabilities (refer note below) (17) Vet cash used in financing activities (C) (2,124) Vet increase/ (decrease) in cash and cash equivalents (A+B+C) 57 Cash and cash equivalents as at the beginning of the year 55 Cash and cash equivalents as at the end of the year 55 Cash and cash equivalents as at the end of the year 112 Vote: Movement in borrowings and lease liabilities in accordance with Ind AS 7: 112 Current borrowings 3,632 1,5 Copening balance 3,632 1,5 Repayment of)/ Net proceeds from short-term borrowings (9) 2,731 3,6 Venese liabilities 29 2,731 3,6 Cash flow changes 29 29 29	Dividends paid	(1,078)	(1,708)	
Net cash used in financing activities (C) (2,124) (2,37) Net increase/ (decrease) in cash and cash equivalents (A+B+C) 57 (1 Cash and cash equivalents as at the beginning of the year 55 (1 Cash and cash equivalents as at the end of the year 55 (1 Cash and cash equivalents as at the end of the year 112 55 Cash and cash equivalents as at the end of the year 112 55 Note: Movement in borrowings and lease liabilities in accordance with Ind AS 7: 112 55 Current borrowings 3,632 1,5 Opening balance 3,632 1,5 Repayment of)/ Net proceeds from short-term borrowings (9) 2,731 3,6 Non-cash items (Foreign exchange changes) 2,731 3,6 2,731 3,6 Lease liabilities 29 2,731 3,6 29 <	Finance cost paid	(137)	(141)	
Net increase/ (decrease) in cash and cash equivalents (A+B+C) 57 (1) Cash and cash equivalents as at the beginning of the year 55 (1) Cash and cash equivalents as at the end of the year 112 55 Cash and cash equivalents as at the end of the year 112 55 Note: Movement in borrowings and lease liabilities in accordance with Ind AS 7: 112 55 Current borrowings 3,632 1,5 Opening balance 3,632 1,5 Repayment of)/ Net proceeds from short-term borrowings (892) 2,0 Non-cash items (Foreign exchange changes) (9) 2,731 3,6 Lease liabilities 29 29 29 29 Cash flow changes (17) (17) (17)	Principal and interest payment of lease liabilities (refer note below)	(17)	(16)	
Cash and cash equivalents as at the beginning of the year 55 Cash and cash equivalents as at the end of the year 112 Solar cash equivalents as at the end of the year 112 Note: Movement in borrowings and lease liabilities in accordance with Ind AS 7: 112 Current borrowings 3,632 1,5 Opening balance 3,632 1,5 Non-cash items (Foreign exchange changes) (9) 2,731 Lease liabilities 29 29 Cash flow changes (17) (17)	Net cash used in financing activities (C)	(2,124)	(2,373)	
Cash and cash equivalents as at the beginning of the year 55 Cash and cash equivalents as at the end of the year 112 Solar cash equivalents as at the end of the year 112 Note: Movement in borrowings and lease liabilities in accordance with Ind AS 7: 112 Current borrowings 3,632 1,5 Opening balance 3,632 1,5 Non-cash items (Foreign exchange changes) (9) 2,731 Lease liabilities 29 29 Cash flow changes (17) (17)				
Cash and cash equivalents as at the end of the year 112 112 Note: Movement in borrowings and lease liabilities in accordance with Ind AS 7:	Net increase/ (decrease) in cash and cash equivalents (A+B+C)	57	(14	
Note: Movement in borrowings and lease liabilities in accordance with Ind AS 7:	Cash and cash equivalents as at the beginning of the year		69	
Current borrowings 3,632 1,5 Depening balance 3,632 1,5 Repayment of)/ Net proceeds from short-term borrowings (892) 2,0 Non-cash items (Foreign exchange changes) (9) 2,731 3,63 Lease liabilities 29 29 Cash flow changes (17) (17)	Cash and cash equivalents as at the end of the year	112	55	
Opening balance 3,632 1,5 Repayment of)/ Net proceeds from short-term borrowings (892) 2,0 Non-cash items (Foreign exchange changes) (9) 2,731 3,63 Lease liabilities 29 29 Cash flow changes (17) (17)	Note: Movement in borrowings and lease liabilities in accordance with Ind AS 7:			
Opening balance 3,632 1,5 Repayment of)/ Net proceeds from short-term borrowings (892) 2,0 Non-cash items (Foreign exchange changes) (9) 2,731 3,63 Lease liabilities 29 29 Cash flow changes (17) (17)	Current borrowings			
Non-cash items (Foreign exchange changes) (9) Lease liabilities 2,731 3,60 Dening balance 29 29 Cash flow changes (17) (17)	Opening balance	3,632	1,599	
Non-cash items (Foreign exchange changes) (9) Lease liabilities 2,731 3,60 Dening balance 29 29 Cash flow changes (17) (17)	(Repayment of)/ Net proceeds from short-term borrowings	(892)	2,029	
Lease liabilities2,7313,6Dening balance29Cash flow changes(17)	Non-cash items (Foreign exchange changes)		4	
Lease liabilities 29 Opening balance 29 Cash flow changes (17)			3,632	
Cash flow changes (17)	Lease liabilities			
Cash flow changes (17)	Opening balance	29	12	
	Cash flow changes	1000 C	(16	
	Non-cash changes		33	
		1.	29	

Continued ... A. NA NATCO ÷ Vderab



Notes to the audited standalone financial results:

- The audited standalone financial results of NATCO Pharma Limited ("the Company") have been prepared in accordance with the Indian Accounting Standards (Ind AS) prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules issued thereunder and in terms of Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- 2) The audited standalone financial results for the quarter and year ended 31-03-2025 have been reviewed by the Audit Committee of the Board and approved by the Board of Directors of the Company at their meetings held on 28-05-2025.
- 3) The audited standalone financial results of the Company for the quarter and year ended 31-03-2025, have been audited by the statutory auditors and they have issued an unmodified audit report on the same. The audit report of the statutory auditors is being filed with the National Stock Exchange of India Limited ('NSE') and BSE Limited ('BSE') and is also available on the Company's website.
- 4) The standalone figures for the quarter ended 31-03-2025 and 31-03-2024 as reported in these audited standalone financial results are the balancing figures between standalone audited figures in respect of the full financial years and the published unaudited year to date standalone figures up to the third quarter of the respective financial years. The figures up to the end of the third quarter were only reviewed and not subjected to audit.
- 5) Where financial results contain both consolidated and standalone financial results of the parent, segment information is required to be presented only in the consolidated financial results. Accordingly, segment information has been presented in the audited consolidated financial results.
- 6) The audited financial results of the following subsidiaries and step-down subsidiaries of the Company are included in the consolidated financial results for the quarter and year ended 31-03-2025:

S.No	Name of the entity	Country	Relationship
1	NATCO Pharma Inc.	United States of America	Wholly owned Subsidiary
2	NATCO Pharma USA LLC	United States of America	Step-down Subsidiary
3	Time Cap Overseas Limited	Mauritius	Wholly owned Subsidiary
4	NatcoFarma do Brasil Ltda.	Brazil	Step-down Subsidiary
5	NATCO Pharma (Canada) Inc.	Canada	Wholly owned Subsidiary
6	NATCO Pharma Asia Pte. Ltd.	Singapore	Wholly owned Subsidiary
7	NATCO Pharma Australia PTY Ltd.	Australia	Wholly owned Subsidiary
8	NATCO Lifesciences Philippines Inc.	Philippines	Wholly owned Subsidiary
9	NATCO Pharma UK Limited (w.e.f. 04-09-2023)	United Kingdom	Wholly owned Subsidiary
	PT.NATCO Lotus Farma (w.e.f. 28-08-2023)	Indonesia	Subsidiary
11	NATCO Pharma Colombia S.A.S. (w.e.f. 15-08-2023)	Colombia	Wholly owned Subsidiary

- 7) During the quarter and year ended 31-03-2025, the Company has recognised an impairment loss of ₹ 500 million on account of impairment of property, plant and equipment of Agro Chemical segment.
- 8) The Board of Directors at their meeting held on 12-02-2025 had approved an interim dividend of ₹ 1.5/- per equity share of ₹ 2 each for the quarter ended 31-12-2024. An interim dividend of ₹ 3 /- per equity share of ₹ 2 each for the quarter ended 30-06-2024 and an interim dividend of ₹ 1.5 /- per equity share of ₹ 2 each for the quarter ended 30-09-2024 was approved by Board of Directors at their meetings held on 12-08-2024 and 12-11-2024 respectively. The total dividend for the financial year ended 31-03-2025 works out to ₹ 6/- per equity share on equity shares of ₹ 2 each.

By order of the Board For NATCO Pharma Limited

NATCO V C Nannapaneni Chairman & Managing Director (DIN: 00183315)

Place: Hyderabad Date: 28 May 2025